Project description:A toxicogenomic analysis from liver of different pharmacological active coumarins (mammea A/BA+A/BB 3:1 and soulatrolide ) was performed on mice treated (20mg/kg/daily) for a whole week to evaluate if such compounds possess or could develop a hazardous profile on liver. In this dataset, we include the expression data obtained from dissected liver mouse treated with active coumarins (obtained from Calophyllum brasiliense) and control (SSI) for a whole week. Livers from 4 animals per treatment and control were subjected to RNA extraction. These data showed 46 genes up and 72 downregulated genes for mammea coumarins and 665 up and 1077 downregulated genes . Expression data from liver of mice treated with different coumarins (mammea and soulatrolide) from Calophyllum brasiliense 12 Total samples were analyzed. Liver from 4 animals per treatment groups were subjected to mRNA expression analysis. We generated the statistical computing and metrics in the arrayQualityMetrics data were normalized with RMA method and differential expressed genes obtained with Ingenuity Software. Genes with an FDRâ¤10% and a fold-change â¥2 were selected.
Project description:Primary objectives: The primary objective is to investigate circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).
Primary endpoints: circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).
